Beckman Coulter — Q3 2009 Earnings Presentation
16 slides from Beckman Coulter's earnings presentation, Oct 29, 2009
Slide 1: Beckman Coulter Q3 2009 Financial Presentation
1 BEC Q3 2009 Conf Call & Beckman Coulter Q3 2009 – Financial Presentation Scott Garrett Chairman, President & Chief Executive Officer Exhibit 99.2
Slide 2: Key Points Q3 2009
Key Points Q3 2009 Core Business (ex. ODS) performing well: #1 - Recurring Revenue: 7.7% (cc) #2 - Cash Instrument Sales: 15% (cc) #3 - Operating Income Margin: 13.5% #4 - Expanded Earnings and Cash Flow EPS: $0.95 Free Cash Flow YTD: > $180M
Slide 3: Strength in Diagnostics - Recurring Revenue
Strength in Diagnostics- ex ODS 8.4% (cc) AutoChemistry and Immunoassay growing above market Access Immunoassay growing >10% (cc) Recurring Revenue: Q3 2009 ($ millions) Product Area Beckman Coulter Olympus Diagnostics (ODS) Consolidated Total Recurring Revenue % Chg in constant currency $620.2 7.7%
Slide 4: Cash Instrument Sales
Deferred instrument renewals Weakness in Cellular and Life Science Prior year comparables Challenging economic environment Cash Instrument Sales: Q3 2009 ($ millions) Product Area Beckman Coulter Olympus Diagnostics (ODS) Consolidated Total Cash Instrument Sales % Chg in constant currency $137.5 (14
Slide 5: Revenue by Geography
Revenue by Geography: Q3 2009 ($ millions) Beckman Coulter Olympus Diagnostics (ODS) Consolidated United States % Chg $381.0 1.2% $21.2 $402.2 6.8% International % Chg in constant currency $376.8 4.4% $43.9 $420.6 16.2% United States: Recurring revenue growing mid-single digits Life Science 7% Inter
Slide 6: Olympus Integration
Olympus Integration Progress to Date Integration is meeting expectations 2010 Anticipated Synergies: $50 to $60M R&D: $20M Discontinued Immunoassay R&D Selling Expense: $25M Eliminated redundancies to achieve 2010 run rate by year-end General and Admin.: $5-15M Still working through transition servi
Slide 7: Financial Presentation - Charlie Slacik, CFO
7 BEC Q3 2009 Conf Call & Beckman Coulter Q3 2009 – Financial Presentation Charlie Slacik SVP & Chief Financial Officer
Slide 8: 2009 Outlook
2009 Outlook- (ex ODS) Provided 10/29/09 Total revenue: Reported Flat Constant currency 0% to 2% Recurring revenue (cc) 6% to 7% Op income margin ~13% Non-Operating expense ~ $55 M Tax rate ~ 25% CAPEX ~ $325 M Depreciation & Amortization $270 to $290 M EPS (based on ~ 65.5M shares) $3.85 to $3.95 O
Slide 9: Adjusted P & L
Adjusted P & L: Q3 2009 ($ millions) Beckman Coulter Olympus Diagnostics (ODS) Consolidated Revenue: Recurring revenue % Chg in constant currency Cash instrument sales % Chg in constant currency TOTAL % Chg in constant currency $620.2 7.7% 137.5 (14.8%) $757.7 2.8% $55.9 9.2 $65.1 $676.1 17.3% 146.7
Slide 10: Adjusted Non-Op
Adjusted Non-Op*: Q3 2009 ($ millions) Q3 2009 Q3 2008 Change Interest Income ($1.4) ($2.4) ($1.0) Interest Expense $21.9 $16.7 ($5.2) Misc Non-Op $0.0 ($2.0) ($2.0) Total $20.5 $12.3 ($8.2) * Excludes Olympus Acquisition related currency gains
Slide 11: Adjusted P & L: YTD
Adjusted P & L: YTD Q3 2009 ($ millions) Beckman Coulter Olympus Diagnostics (ODS) Consolidated Revenue: Recurring revenue % Chg in constant currency Cash instrument sales % Chg in constant currency TOTAL % Chg in constant currency $1,822.9 6.8% 383.0 (20.1%) $2,205.9 0.9% $55.9 9.2 $65.1 $1,878.8 1
Slide 12: Balance Sheet & Cash Flow
Balance Sheet & Cash Flow YTD Q3 2009 CAPEX: $18M Increase in PP&E CAPEX offset by decrease in OTL CAPEX DSO (ex ODS): 4 day improvement Inventory turns (ex ODS): 3.0 to 3.1 (cc) Adjusted EBITDA TTM: $675M 12% Operating cash flow: $158M to $402M YTD Free cash flow > $180M YTD
Slide 13: Beckman Coulter Q3 2009 Financial Presentation
13 BEC Q3 2009 Conf Call & Beckman Coulter Q3 2009 – Financial Presentation
Slide 14: Concluding Remarks
Concluding Remarks YTD Q3 2009 Recurring revenue*: 6.8% (cc) Adjusted operating expense*: 3% (cc) Olympus update: Rationale: Reach into high-volume labs, extending cross-selling Integration: Synergies on plan 2010 preliminary outlook, including Olympus, on December 17, 2009 at our Annual Business Re
Slide 15: Beckman Coulter Q3 2009 Financial Presentation
15 BEC Q3 2009 Conf Call & Beckman Coulter Q3 2009 – Financial Presentation
Slide 16: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements expectat